Posted by Daniel Bedinger PhD
Related Literature: Science Paper
Denisa Foster, Biochemist, Lilly’s Protein Biosciences group
The quick emergence and pandemic spread of SARS-CoV-2 called for a multi-pronged response from the scientific community. In addition to anti-viral therapies and vaccines, monoclonal antibodies (mAbs) provide a promising tool in the fight against COVID and much more.
At Lilly, in collaboration with AbCellera, antibodies were identified that disrupt binding of the virus to the human receptor ACE2 and show potent viral neutralization.
This webcast will showcase the use of Carterra’s LSA platform at different stages of the discovery and characterization process of LY-CoV555, using high-throughput surface plasmon resonance (HT-SPR) to obtain affinities, epitope binning and ACE2 blocking.
Denisa Foster, Biochemist at Lilly Protein Biosciences, and Daniel Bedinger PhD, Applications Science Team Lead from Carterra, will host a Q&A.
The presentation will focus on: